MYELOID THERAPEUTICS
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
MYELOID THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.myeloidtx.com
Total Employee:
11+
Status:
Active
Total Funding:
50 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network GStatic Google Static Content Sectigo SSL Sectigo Domain SSL Wix
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Lytica Therapeutics
Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Myeloid Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series A - Myeloid Therapeutics
8VC
8VC investment in Series A - Myeloid Therapeutics
Newpath Management
Newpath Management investment in Series A - Myeloid Therapeutics
Official Site Inspections
http://www.myeloidtx.com
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Myeloid Therapeutics"
Myeloid Therapeutics - The Leaders in mRNA-based …
Aug 29, 2024 · Discover our groundbreaking cancer treatments and explore innovative approaches to harnessing myeloid cells for targeted cancer therapies.See details»
Our Mission - Myeloid Therapeutics
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells.See details»
Our Team - Myeloid Therapeutics
Myeloid is powered by our team of talented, driven scientists and biotech industry experts whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery.See details»
Myeloid Therapeutics - LinkedIn
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells.See details»
Myeloid Therapeutics - Crunchbase Company Profile
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases. Myeloid Therapeutics may be growing as evidenced by their active participation in …See details»
Myeloid Therapeutics Announces $73 Million Financing to …
May 18, 2023 · Financing accelerates MT-302, the Company's first clinical candidate for in vivo cell programming, into a Phase 1/2 clinical trial for TROP2+ solid tumors.See details»
Jerome Chal, PhD - Myeloid Therapeutics
Dr. Chal joined Myeloid in April 2022 as our Senior Vice President, Head of CMC. Dr. Chal brings to Myeloid over twenty years of experience in the biotechnology industry, with a focus on CMC …See details»
Myeloid Therapeutics Launches with Over $50 Million in Financing …
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells for treating cancers, launched today with over …See details»
Myeloid Therapeutics Initiates Patient Dosing with MT-303, a …
Jul 31, 2024 · Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, has dosed the first patient with MT-303 in a …See details»
Myeloid Therapeutics Doses First Patient with MT-101 …
CAMBRIDGE, Mass., May 11, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid", or the "Company"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and...See details»
Myeloid Therapeutics Doses First Patient with MT-101 …
May 11, 2022 · Myeloid's proprietary ATAK platform is designed to harness the innate abilities of myeloid cells. When applied to a therapeutic candidate, the immunotherapy recognizes cancer cells, alters the tumor microenvironment, …See details»
Myeloid Therapeutics Strengthens Senior Team to Support the
Aug 23, 2022 · Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company harnessing the power of myeloid cell biology to engineer new therapeutic alternatives for …See details»
Our Science - Myeloid Therapeutics
Our mRNA technologies utilize myeloid cells to engulf cancer cells, produce anti-tumor agents, promote anti-tumor adaptive immunity, and alter the tumor microenvironment. Our capabilities …See details»
Myeloid Therapeutics Initiates Patient Dosing with MT-302, a
Sep 12, 2023 · Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic epithelial …See details»
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial ...
Jan 11, 2021 · Myeloid Therapeutics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation ® technology and ExPERT™ platform. This agreement …See details»
Myeloid cell-targeted therapies for solid tumours - Nature
Jun 13, 2022 · In this Review, we highlight key features of monocyte and macrophage biology that are being explored as potential targets for cancer therapies and what aspects of myeloid cells …See details»
Myeloid Therapeutics Strengthens Senior Team to Support the …
CAMBRIDGE, Mass, August 23, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to …See details»
Myeloid Therapeutics Initiates Patient Dosing with MT
Jul 31, 2024 · MT-303 is Myeloid’s second in vivo mRNA CAR program to enter the clinic from its pipeline of in vivo immune cell programming therapies. Dosing with MT-303 represents a …See details»
Myeloid Therapeutics to Participate in Jefferies London Healthcare ...
CAMBRIDGE, Mass., November 13, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer …See details»